Navigation Links
Oncothyreon regains compliance with NASDAQ listing requirements

SEATTLE, March 16 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that on March 12, 2009, it received a notice from the NASDAQ Hearings Panel that Oncothyreon had re-gained full compliance with the continued listing standards of The NASDAQ Global Market.

The notice followed a review of Oncothyreon's 2008 financial results, in which Oncothyreon reported that its stockholders' equity as of December 31, 2008 was $20,717,000. Based on this review, the staff of the NASDAQ Hearings Panel determined that Oncothyreon had regained compliance with the continued listing requirements in NASDAQ Marketplace Rule 4450 and notified Oncothyreon that the matter is now closed.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit

Forward-Looking Statements

In order to provide our investors with an understanding of our current condition and future prospects, this release contains statements that are forward-looking. These forward-looking statements include statements related to our ability to maintain compliance with the listing standards of The NASDAQ Stock Market. Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the availability and adequacy of financing, our financial condition and results of operations, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon to present at Invest Northwest 2009
2. Oncothyreon reports full year and fourth quarter 2008 financial results
3. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
4. Oncothyreon to present at BIO CEO & Investor Conference 2009
5. Oncothyreon reports third quarter 2008 financial results
6. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
7. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
8. Oncothyreon to present at BIO Investor Forum 2008
9. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
10. Oncothyreon announces prioritization plan for development programs
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time in ... STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, ... , US2020’s mission is to change the trajectory of STEM education in America ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):